This description describes a new actriib-ecd hybrid polypeptide. This note provides methods for the treatment or prevention of muscle atrophy, skeletal diseases, metabolic diseases, fibrosis, autoimmune/inflammatory diseases, cardiovascular diseases, cancer or cancer, and chronic kidney diseases.Arthritis, anorexia, liver disease, rejection of organ or tissue transplantation, anemia, pain and/or aging are in need. In addition, this note provides a method for inducing stem cell growth to repair tissue or organ regeneration in an object. The above methods include mixing a polypeptide diluent from Lig into the target body in an effective way.I'm acting. 2. This note also provides a variety of drug synthesis, including a mixture of polypeptide Trap from Ligando actriib the present disclosure description novel hybrid soluble actriib-ecd polypepptides. The present disclosure provides methods for treating or preventing muscle wastingBone Disease, a Metabolic, Fibrosis, an autoimmune/inflammatory, cardiovascular disease, cancer or cancer, chronic kidney disease (CKD),Arthritis, anorexia, living diseases, organ or tissue transplantation disorders, anemia, Pain and/or aging when needed. In addition, current emissions of Tissue repairs or organic regeneration provide a way to induce current cell growth. The aforementioned methods include administering to the subject a therapeutically effective amount of a hybrid actriib ligand trap polypeppetide. The present disclosure also provides pharmaceutical compositions comprising hybrid actriib ligand trap polypticides.La presente descripción describe polipéptidos híbridos ActRIIB-ECD solubles novedosos. La presente descripción proporciona métodos para el tratamiento o la prevención de la atrofia muscular, enfermedad ósea, una enfermedad metabólica, fibrosis, una enfermedad autoinmune/inflamatoria, una enfermedad cardiovascular, cáncer o cáncer, enfermedad renal crónica (CKD), artritis, anorexia, enfermedad hepática, rechazo de traspla
